1 / 27

Management of Nausea and Vomiting

Management of Nausea and Vomiting. John A. Mulder, MD Vice President, Medical Services Faith Hospice. Onset Frequency Relationship to eating Relationship to medications Current nausea medications. Chronic or progressing Alleviating factors Severity Scale: 1-10 Goal. Assessment.

hastin
Download Presentation

Management of Nausea and Vomiting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Nausea and Vomiting John A. Mulder, MD Vice President, Medical Services Faith Hospice

  2. Onset Frequency Relationship to eating Relationship to medications Current nausea medications Chronic or progressing Alleviating factors Severity Scale: 1-10 Goal Assessment

  3. Assess cause: • Chemoreceptor trigger zone (CTZ) • Gastrointestinal/bowel • Vestibular • Cortical/anxiety • Vomiting center

  4. Opioids (and metabolites) Intracranial pressure Metabolic problems NAUSEA Other drugs Constipation Bowel obstruction Peptic ulcer disease Autonomic failure Driver, L, and Bruera, E., The MD Anderson Palliative Care Handbook

  5. Common Causes in Cancer Patients • Treatment-related factors • Chemotherapy • Radiation Therapy • Opioid Therapy • Other drugs (antibiotics, NSAIDs, SSRIs, etc.)

  6. Common Causes in Cancer Patients • Pathophysiologic/metabolic/biochemical • Constipation • Autonomic dysfunction (gatroparesis, stasis) • Gastric/duodenal ulcer • GERD/gastritis • Liver failure/hepatomegaly/ascites • Infection/sepsis/fever • Coughing • Increased intracranial pressure

  7. Common Causes in Cancer Patients • Pathophysiologic/metabolic/biochemical • Oral/esophageal infection/lesions • Pain • Dehydration • Electrolyte imbalance • Hypercalcemia • Uremia • Endocrine dysfunction

  8. Common Causes in Cancer Patients • CNS/psychophysiologic problems • Vestibular disturbance • Cerebrocortical mechanisms (anticipatory N/V) • Limbic mechanisms (hypersensitivity to taste and smell) • Anxiety

  9. Most patients have multifactoral causes

  10. Treatment Considerations • Constipation regimen • Decompress obstruction; disimpact • If no nausea and tolerated, support only • Oral hygiene • Small stomach: small portions, frequent meals, cold foods tolerated better • Odors • Avoid odors of cooking (ventilation) • Perfumes, scents, etc.

  11. Opioid rotation • Steroids or RT for increased ICP • Reassurance/relaxation for anticipatory nausea/high anxiety • Correct electrolyte imbalance • Volume repletion for dehydration • Hypercalcemia treatment with hydration, steroids, bisphosphonates • Adjustment of nutritional supplements

  12. Review medication list • a. Digitalis • b. Theophylline • c. Chemotherapy • d. Antibiotics • 1. Erythromycin • 2. Tetracycline • 3. Metronidazole (Flagyl) • 4. Ciprofloxacin (Cipro)

  13. Pharmacologic treatment Conventional antiemetics : • metoclopramide(Reglan) – po, pr, iv, sc • prochlorperazine (Compazine) - po, pr, iv, sc • droperidol(Inapsine) - im, iv, sc • promethazine (Phenergan) - po, pr, iv, sc • scopolomine (TransdermScop, Scopace) – td, po • meclizine (Antivert) - po

  14. Pharmacologic treatment Selective serotonin 5-HT3 antagonists: • ondansetron(Zofran, Zuplenz) - po, iv, sc, sl • granisetron(Kytril, Granisol, Sancuso) - po, iv, sc, td • polonosetron (Aloxi) – iv • dolasetron (Anzemet) – iv

  15. Pharmacologic treatment Cannabinoid receptor agonists: • nabilone (Cesamet) – PO • dronabinol (Marinol) – PO

  16. Pharmacologic treatment Others: • aprepitant (Emend) – PO, IV • Selective human substance P/neurokinin 1 receptor antagonist

  17. Anticholinergic agents • Hyoscyamine (Levsin) Motility Problem • a. Metoclopramide (Reglan) 5-20mg a.c. • b. Cisapride (Propulsid) 10-20mg QID Movement induced; initiation of opioids • a. Scopolamine (Transderm Scop Patch) Q 72hrs • b. Meclizine (Antivert) 12.5-25mg Q 6hrs

  18. Alternative antiemetics (cont.) • d. Combination suppositories: BRD • 1. Benadryl 25 mg • 2 .Reglan 10 mg 1-2 PR Q 4hr • 3. Dexamethasone 2 mg • e. ABHR • 1. Ativan 0.5 mg • 2. Benedryl 12.5 mg 1 Q 6hr • 3. Haldol 0.5 mg • 4. Reglan 10 mg

  19. Unconventional antiemetics : • Haloperidol (Haldol) • Lorazepam (Ativan) • Diphenhydramine (Benadryl) • Corticosteroids (Decadron) • Sea Bands • Cannabinoids (Marinol)

  20. BAD Drip • 50 cc D5W • 200 mg Benedryl • 8 mg Ativan • 20 mg Decadron • 0.2 – 2.0 ml/h

  21. RBD Drip • 50 cc 0.9% sodium chloride • 80 mg Reglan • 100 mg Benadryl • 8 mg Decadron • 0.5 – 1.5 ml/h

  22. Random thoughts . . . • Metoclopramide 1st drug of choice because of peripheral (GI) effects and central effects (CTZ) • Antihistamines have no antidopaminergic effect (not 1st line in treating opioid-related nausea) • Phenothiazines very sedating, can cause other side effects • NG tube may be necessary for mgmt of copious vomiting, abd distention, obstruction, etc. • Combining drugs of different mechanisms may yield positive results in addressing multifactoral etiology

  23. Random thoughts . . . • Anticipatory, PO, RTC dosing most likely to provide greatest benefit • Corticosteroids often exert excellent antiemetic effects • Always R/O constipation/impaction in terminally ill patient presenting with chronic N/V • 5-HT3 antagonists among most effective for chemotherapy induced N/V, but have minial effects on opioid-induced emesis and have no promotility effects

  24. Costs

  25. Costs

  26. Costs

  27. John Mulder, MD VP of Medical Services Faith Hospice 616-293-3615 john.mulder@hollandhome.org

More Related